top of page

WHAT WE DO?

Malaria represents one of the main Public Health problems with greater weight in morbidity and mortality, in the world and in Mozambique in particular. According to the WHO, it is estimated that in 2018 about 228 million cases of malaria and 405 thousand deaths were estimated globally; of these cases, 93% (213 million) occurred in sub-Saharan Africa. Mozambique is one of the ten countries with the highest weight of malaria in the world, with the disease being responsible for about 29% of all deaths (42% in children under 5 years old). Data from the survey of malaria indicators carried out in 2018, indicate that the prevalence of malaria in children under 5 years old was 39% in Mozambique, ranging from 1% in the City and Province of Maputo to 57% in the province of Cabo Delgado.

 

The investment in research for malaria has been increasing with the relaunch of the objective of eliminating malaria through the global technical strategy for malaria launched in 2015 by WHO; as well as the most recent initiative, also by WHO, called “High Burden High Impact” (HBHI) launched in Maputo in November 2018 which aims to accelerate malaria control measures in 10 African countries plus India. These countries, including Mozambique, contribute more than 70% of the global weight of malaria. Both strategies mentioned above have research as an essential pillar to guide the implementation of activities based on scientific evidence.

The history of CISM is associated with the RTS,S malaria vaccine development initiative, which contributed to the development of human and institutional capacity for research in this area.

The tools currently available are still insufficient to achieve effective malaria control. In addition to the question of the parasite's resistance to antimalarial medication and the vector to insecticides, these tools are not fully effective, and there is a need to continue working on the development of new control tools (prevention and treatment) and/or elimination of malaria.

​

Main objectives

​

  • Design and implement innovative strategies for the control and/or elimination of malaria at different levels of transmission in Mozambique

  • Understand the pathophysiological and immunological mechanisms of malaria, including the identification of critical pathogenic events in parasite sequestration and resistance to antimalarial medication

  • Participate in clinical trials of drugs and vaccines against malaria

  • Develop entomological intelligence and participate in the development of new tools for vector control

  • Develop implementation research, in accordance with the research agenda of the National Malaria Control Program (attached), which can contribute to guide the implementation of the program in the areas of communication for behavior change, vector control, prevention of malaria in pregnancy and case management.

o que fazemos
PI

TEAM

Pedro Aide.jpeg

Pedro Aide

Coordinator

His main area of research is malaria, one of the main health problems that mainly affects children and pregnant women, in Mozambique in particular. He has been involved in several malaria-related research projects as a co-principal investigator and investigator, among other studies on malaria prevention and control, including intermittent preventive treatment trials in infants (IPTi) and clinical evaluation of safety, efficacy and immunogenicity of the most advanced malaria vaccine candidate, RTS, S/AS0. He is currently one of the researchers in the PAMAFRICA project in Mozambique.

Download CV here

  • LinkedIn - círculo cinza

PROJECTS

Projctos

  • AGEAL. Age of Exposure and Immunity to Malaria

  • ASYMPTOM. Unraveling disease tolerance and host resistance in afebrile P. falciparum infections: a prospective study in Mozambican adults

  • BOVA/HUT2. Mosquito screening entry points into houses with novel long-lasting insecticidal netting to reduce indoor vector densities and mitigate pyrethroid-resistance

  • COST. Evaluation of the cost-effectiveness of 3rd generation indoor residual spraying as a malaria control strategy

  • CytoMal. Cellular biomarkers of exposure and immunity to malaria

  • GEPI. Genetic Epidemiology of Plasmodium falciparum in southern Mozambique

  • MAL067. Immunological study of the RTS,S malaria vaccine in the phase 3 trial

  • MANICA. Cross Border Malaria Transmission along the Zimbabwe-Mozambique Border

  • MEFI. Molecular markers of Plasmodium falciparum resistance to antimalarials in different regions of Mozambique

  • MIPMON. Pregnant women as sentinel group for malaria surveillance in an area of ​​changing malaria transmission

  • MOSASWA/VIMAG2. Improved Entomological Intelligence in southern Mozambique

  • SEVMAL2. Identification of strain-transcending anti-adhesion targets from virulent Plasmodium falciparum malaria parasites

  • SYSTEM Health Management Information System Baselin Assessment

  • REACT/MDA. Mass Drug Administration of Monthly DHA-PQP Accelerates Towards Malaria Elimination in Magude District, Southern Mozambique (MDA): Reactive Malaria Case Detection and Response to Towards Malaria Elimination in Southern Mozambique​

  • ROSI Rosiglitazone adjunctive therapy for severe malaria in children

  • TRANSECT/DAYTIME. Transect study in Mnahiça district to inform the extent of larval source management at finer scales + day time biting of malaria mosquitoes

  • VECE-IRS. Assessing the efficacy of vector control tools in killing malaria mosquitoes in Magude and Manhiça district

  • XMAG/XMAL. Transverse Malaria Prevalence Studies in Magude (XMAG) and Manhica (XMAL)

  • XMAL_19. Cross-sectional studies to monitor the burden of malaria and impact of different malaria control tools in Manhiça, Mozambique

Other ongoing projects

Publicações

​LATEST NEWS

PUBLICATIONS (2020)

Authors
Title
Journal
Oruko K, Maixenchs M, Phillips-Howard P, Ondire M, Akelo C, Sanz A, Ordi J, Menéndez C, Bassat Q, Odhiambo FO, Munguambe K.
Conceptual frameworks for understanding the acceptability and feasibility of the minimally invasive autopsy to determine cause of death: Findings from the CADMIA Study in western Kenya.
PLoS One. 2020 Dec 14;15(12):e0242574. doi: 10.1371/journal.pone.0242574. eCollection 2020.PMID: 33315918
Galatas B, Mayor A, Gupta H, Balanza N, Jang IK, Nhamussua L, Simone W, Cisteró P, Chidimatembue A, Munguambe H, Saúte F, Aide P, Bassat Q.
Field performance of ultrasensitive and conventional malaria rapid diagnostic tests in southern Mozambique.
Malar J. 2020 Dec 7;19(1):451. doi: 10.1186/s12936-020-03526-9.PMID: 33287822 
Pons-Duran C, Llach M, Sacoor C, Sanz S, Macete E, Arikpo I, Ramírez M, Meremikwu M, Mbombo Ndombe D, Méndez S, Manun'Ebo MF, Ramananjato R, Rabeza VR, Tholandi M, Roman E, Pagnoni F, González R, Menéndez C.
Coverage of intermittent preventive treatment of malaria in pregnancy in four sub-Saharan countries: findings from household surveys.
Int J Epidemiol. 2020 Dec 8:dyaa233. doi: 10.1093/ije/dyaa233. Online ahead of print.PMID: 33349871
Enguita-Fernàndez C, Alonso Y, Lusengi W, Mayembe A, Manun'Ebo MF, Ranaivontiavina S, Rasoamananjaranahary AM, Mucavele E, Macete E, Nwankwo O, Meremikwu M, Roman E, Pagnoni F, Menéndez C, Munguambe K.
Trust, community health workers and delivery of intermittent preventive treatment of malaria in pregnancy: a comparative qualitative analysis of four sub-Saharan countries.
Glob Public Health. 2020 Dec 8:1-15. doi: 10.1080/17441692.2020.1851742. Online ahead of print.PMID: 33290172
Suau R, Vidal M, Aguilar R, Ruiz-Olalla G, Vázquez-Santiago M, Jairoce C, Nhabomba AJ, Gyan B, Dosoo D, Asante KP, Owusu-Agyei S, Campo JJ, Izquierdo L, Cavanagh D, Coppel RL, Chauhan V, Angov E, Dutta S, Gaur D, Beeson JG, Moncunill G, Dobaño C.
RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
Vaccine. 2020 Dec 24:S0264-410X(20)31606-6. doi: 10.1016/j.vaccine.2020.12.038. Online ahead of print.PMID: 33358704
Bone JN, Pickerill K, Woo Kinshella ML, Vidler M, Craik R, Poston L, Stones W, Sevene E, Temmerman M, Koech Etyang A, Roca A, Russell D, Tribe RM, von Dadelszen P, Magee LA; PRECISE Network.
Pregnancy cohorts and biobanking in sub-Saharan Africa: a systematic review.
BMJ Glob Health. 2020 Nov;5(11):e003716. doi: 10.1136/bmjgh-2020-003716.PMID: 33243854 
Ginsburg AS, Lenahan JL, Jehan F, Bila R, Lamorte A, Hwang J, Madrid L, Nisar MI, Vitorino P, Kanth N, Balcells R, Baloch B, May S, Valente M, Varo R, Nadeem N, Bassat Q, Volpicelli G.
Performance of lung ultrasound in the diagnosis of pediatric pneumonia in Mozambique and Pakistan.
Pediatr Pulmonol. 2020 Nov 18. doi: 10.1002/ppul.25176. Online ahead of print.PMID: 33205892
Colston JM, Faruque ASG, Hossain MJ, Saha D, Kanungo S, Mandomando I, Nisar MI, Zaidi AKM, Omore R, Breiman RF, Sow SO, Roose A, Levine MM, Kotloff KL, Ahmed T, Bessong P, Bhutta Z, Mduma E, Penatero Yori P, Sunder Shrestha P, Olortegui MP, Kang G, Lima AAM, Humphrey J, Prendergast A, Schiaffino F, Zaitchik BF, Kosek MN.
Associations between Household-Level Exposures and All-Cause Diarrhea and Pathogen-Specific Enteric Infections in Children Enrolled in Five Sentinel Surveillance Studies.
Int J Environ Res Public Health. 2020 Nov 2;17(21):8078. doi: 10.3390/ijerph17218078.PMID: 33147841
Valenciano SJ, Moiane B, Lessa FC, Chaúque A, Massora S, Pimenta FC, Mucavele H, Verani JR, da Gloria Carvalho M, Whitney CG, Tembe N, Sigaúque B.
Effect of 10-Valent Pneumococcal Conjugate Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage Among Children Less Than 5 Years Old: 3 Years Post-10-Valent Pneumococcal Conjugate Vaccine Introduction in Mozambique.
J Pediatric Infect Dis Soc. 2020 Nov 27:piaa132. doi: 10.1093/jpids/piaa132. Online ahead of print.PMID: 33245124
Chaguza C, Yang M, Cornick JE, du Plessis M, Gladstone RA, Kwambana-Adams BA, Lo SW, Ebruke C, Tonkin-Hill G, Peno C, Senghore M, Obaro SK, Ousmane S, Pluschke G, Collard JM, Sigaùque B, French N, Klugman KP, Heyderman RS, McGee L, Antonio M, Breiman RF, von Gottberg A, Everett DB, Kadioglu A, Bentley SD.
Bacterial genome-wide association study of hyper-virulent pneumococcal serotype 1 identifies genetic variation associated with neurotropism.
Commun Biol. 2020 Oct 8;3(1):559. doi: 10.1038/s42003-020-01290-9.PMID: 33033372
Magaço A, Munguambe K, Nhacolo A, Ambrósio C, Nhacolo F, Cossa S, Macete E, Mandomando I.
Challenges and needs for social behavioural research and community engagement activities during the COVID-19 pandemic in rural Mozambique.
Glob Public Health. 2020 Oct 30:1-5. doi: 10.1080/17441692.2020.1839933. Online ahead of print.PMID: 33125306
Etti M, Sekikubo M, Nankabirwa V, Sommerfelt H, Freyne B, Kawaza K, Gadama G, Jambo K, Sevene E, Temmerman M, Magee LA, von Dadelszen P, Khalil A, Doare KL; WHO/HRP Alliance author group.
SARS-CoV-2 Infection in Pregnant Women and Their Newborns.
Ann Glob Health. 2020 Oct 8;86(1):132. doi: 10.5334/aogh.3072.PMID: 33102152

Addresses and Contacts

HEADQUARTERS, MANHIÇA, CAMBEVE​ NEIGHBORHOOD

12th Street, CP 1929

Tel: (+258) 21 81 01 81 / 21 81 00 02

MAPUTO CITY OFFICE

Avenida da Marginal, nº 3987, CP 1929

Tel: (+258) 21 49 64 45 / 21 90 01 90

QUELIMANE'S OFFICE

Av. Eduardo Mondlane, 1º de Maio district

(pavé street behind the Holy Squad)

Email: ester.domingos@manhica.net

OFFICE Mopeia

Main Street, Mopeia Headquarters

(Face the workers' square)

Email: victor.macete@manhica.net

An initiative of

bottom of page